UCB S.A.
UCB
株式のランク
#528
UCB S.A., a biopharmaceutical enterprise founded in 1925 and headquartered in... UCB S.A., a biopharmaceutical enterprise founded in 1925 and headquartered in Brussels, Belgium, focuses on developing innovative solutions for individuals living with neurological and immunological diseases. Its diverse commercialized portfolio includes Cimzia, targeting inflammatory TNF-mediated conditions such as Crohn's disease, various forms of spondyloarthritis, rheumatoid arthritis, and psoriasis. For epilepsy management, UCB offers Vimpat, Keppra, and Briviact, along with Nayzilam, an intranasal rescue treatment for seizure clusters. Neupro is available for Parkinson's disease and restless legs syndrome, while Zyrtec and Xyzal address allergy symptoms. Other key products include Evenity for osteoporosis in postmenopausal women, and BIMZELX, which treats psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa. The company also provides dapirolizumab pegol for systemic lupus erythematosus. UCB's robust development pipeline features candidates like rozanolixizumab, aimed at myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan for myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam for prolonged seizures; Bepranemab for Alzheimer's disease; and UCB0599 for Parkinson's disease. Beyond its proprietary drug development, UCB also conducts contract manufacturing. The company engages in significant collaborations with entities such as Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. UCB's global footprint extends across numerous countries, including the United States, Japan, China, Belgium, and a broad presence throughout Europe, encompassing Germany, Spain, France, Italy, the United Kingdom, and Ireland.
株価
$242.09
最終同期: 2026-10-16
時価総額
$46.16B
変化（1日）
-0.92%
変化（1年）
-16.48%
国
BE
取引 UCB S.A. (UCB)
カテゴリー
Healthcare
UCB S.A.（UCB）の営業利益率
October 2026 時点の営業利益率 TTM: 31.23%
UCB S.A. の最新の財務報告と株価によると、現在の営業利益率（TTM）は 31.23% です。2023 年末時点では 11.50% でした。
UCB S.A. の営業利益率の履歴（2002 から 2026）
各年末の営業利益率
| 年 | 営業利益率 | 変化 |
|---|---|---|
| 2026 (TTM) | 31.23% | 45.12% |
| 2024 | 21.52% | 87.13% |
| 2023 | 11.50% | 58.62% |
| 2022 | 7.25% | -63.48% |
| 2021 | 19.85% | 8.65% |
| 2020 | 18.27% | -17.18% |
| 2019 | 22.06% | -8.12% |
| 2018 | 24.01% | -0.08% |
| 2017 | 24.03% | 25.22% |
| 2016 | 19.19% | 28.88% |
| 2015 | 14.89% | 31.07% |
| 2014 | 11.36% | 16.27% |
| 2013 | 9.77% | -13.08% |
| 2012 | 11.24% | 6.04% |
| 2011 | 10.60% | 67.19% |
| 2010 | 6.34% | -76.40% |
| 2009 | 26.86% | 755.41% |
| 2008 | 3.14% | -66.91% |
| 2007 | 9.49% | -58.06% |
| 2006 | 22.63% | 45.53% |
| 2005 | 15.55% | 13.50% |
| 2004 | 13.70% | -6.29% |
| 2003 | 14.62% | 64.09% |
| 2002 | 8.91% | 0.00% |
同業他社の営業利益率
| 企業 | 営業利益率 | 営業利益率の差 | 国 |
|---|---|---|---|
| 38.59% | -98.76% |
US
|
|
| -149.01% | -104.77% |
US
|
|
| 25.57% | -99.18% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -99.08% |
NL
|
企業の営業利益率とは？
営業利益率は、企業の収益性を評価するための重要な指標です。高い営業利益率は一般的に良いとされており、企業が製品やサービスをその生産コストよりもはるかに高く販売できていることを示します。営業利益率は、企業の利益を売上高で割ることで計算されます。